Home › Merck Animal Health Receives FDA Approval of BRAVECTO (fluralaner topical solution) for Cats and Dogs
 

Keywords :   


Merck Animal Health Receives FDA Approval of BRAVECTO (fluralaner topical solution) for Cats and Dogs

2016-07-21 23:00:00| Merck.com - Corporate News

Dateline City: MADISON, N.J. Topical Treatment for Fleas and Ticks Effective for up to 12 Weeks MADISON, N.J.--(BUSINESS WIRE)--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, today announced the U.S. Food and Drug Administrations approval of BRAVECTO (fluralaner topical solution) for both cats and dogs, a topical treatment for fleas and ticks effective for up to 12 weeks1,2 following a single dose. Language: English Contact: Merck Animal HealthMedia:Kelly Goss, 913-558-6452 kelly.goss@merck.com orPamela Eisele, 267-305-3558 pamela.eisele@merck.com orInvestor Relations:Amy Klug, 908-740-1898 amy.klug@merck.com Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: health solution animal approval

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
20.05Eastern North Pacific Tropical Weather Outlook
20.05Atlantic Tropical Weather Outlook
19.05Atlantic Tropical Weather Outlook
19.05Eastern North Pacific Tropical Weather Outlook
19.05IT Cosmetics and Kenvue Launch New Products
19.05Virgin Trains targets West Coast in return to rail
19.05Cashing In On The Stache
19.05 Dr. Squatch Launches Bronco Bricc
More »